Researchers from MIT and McMaster University have used artificial intelligence to identify a new antibiotic that can fight against a drug-resistant bacteria commonly found in hospitals and medical offices, reports Ken Alltucker for USA Today. The researchers believe the AI “process used to winnow thousands of potential drugs to identify one that may work is an approach that can work in drug discovery,” writes Alltucker.
Researchers from MIT and elsewhere have used artificial intelligence to develop a new antibiotic to address Acinetobacter baumannii, a bacteria known for infecting wounds, lungs and kidneys, reports Harland-Dunaway for The World.
Using a machine-learning algorithm, researchers from MIT and McMaster University have discovered a new type of antibiotic that works against a type of drug-resistant bacteria, reports Brenda Goodman for CNN. Goodman notes that the compound “worked in a way that stymied only the problem pathogen. It didn’t seem to kill the many other species of beneficial bacteria that live in the gut or on the skin, making it a rare narrowly targeted agent.”
Researchers from MIT and McMaster University used a machine-learning algorithm to identify a new antibiotic that can treat a bacteria that causes deadly infections, reports Maya Yang for The Guardian. The researchers used an “AI algorithm to screen thousands of antibacterial molecules in an attempt to predict new structural classes. As a result of the AI screening, researchers were able to identify a new antibacterial compound which they named abaucin,” writes Yang.
Researchers from MIT and Harvard Medical School are investigating how exercise and high-fat diets can alter cells, genes and cellular pathways, reports Abby Patkin for Boston.com. “Their research could eventually help develop drugs that would mimic the effects of exercise and combat obesity,” explains Patkin.
Researchers from MIT and Harvard Medical School have conducted a study to see how exercise and high-fat diets can impact cells, reports WCVB. The researchers “say the data could eventually be used to develop drugs that could help enhance or mimic the benefits of exercise,” writes WCVB.
A new study by researchers from MIT and Harvard Medical School has helped identify the impact of exercise and high-fat diets on cells, reports Darren Botelho for NBC Boston 10. “Years from now, those researchers say the data could lead to a pill that would help not only with weight loss, but with the overall effect from exercise – a better wellbeing,” explains Botelho.
Prof. Manolis Kellis speaks with Boston 25 about his team’s work exploring the underlying mechanisms exploring how exercise influences weight loss, findings that could offer potential targets for drugs that could help to enhance or mimic the benefits of exercise. “Such an intervention would be a complete game changer and the reason for that is that the obesity epidemic has led to the U.S. having a decreased life span compared to all other developed countries,” says Kellis.
Scientists from MIT, Georgia Institute of Technology, Sun Yat-sen University and Beijing-based AI startup Galixir have developed a deep-learning toolkit that can predict biosynthetic pathways for natural products, which are a primary source of clinical drug discovery, reports Xinhua Net. “The researchers presented a toolkit called Bionavi-NP to propose NP biosynthetic pathways from simple building blocks in an oprtimal fashion, which requires no already-known biochemical rules,” writes Xinhua Net.
Boston Herald reporter Rick Sobey writes that a new drug combination has shown potential in treating pancreatic cancer. “The trio drug combination is a CD40 agonist antibody, a PD-1 inhibitor and a TIGIT inhibitor. The researchers found that this combination led to pancreatic tumors shrinking in about 50% of the animals that were given this treatment,” writes Sobey.
Prof. Heidi Williams speaks with Callie Crossley as part of WGBH’s “Genius Next Door” series, which features local winners of the MacArthur “genius grant.” Williams explains that her work focuses on “whether we're getting the right kinds of medical technologies developed.”